Filing Details

Accession Number:
0001104659-16-108207
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-29 12:00:08
Reporting Period:
2016-03-29
Filing Date:
2016-03-29
Accepted Time:
2016-03-29 12:00:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1626971 Corvus Pharmaceuticals Inc. CRVS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1357522 A. Peter Thompson C/O Corvus Pharmaceuticals, Inc.
863 Mitten Road, Suite 102
Burlingame CA 94010
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2016-03-29 3,994,674 $0.00 3,994,674 No 4 C Indirect See Footnotes
Common Stock, $0.0001 Par Value Acquisiton 2016-03-29 713,776 $0.00 4,708,450 No 4 C Indirect See Footnotes
Common Stock, $0.0001 Par Value Acquisiton 2016-03-29 550,000 $15.00 5,258,450 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2016-03-29 3,994,674 $0.00 3,994,674 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2016-03-29 713,776 $0.00 713,776 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of the Issuer's initial public offering.
  2. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.
  3. Each of GP V, Advisors, Isaly and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  4. The expiration date is not relevant to the conversion of these securities.
  5. OPI V purchased an additional 550,000 shares of the Issuer's common stock in connection with the Issuer's initial public offering at the offering price of $15.00 per share.